The harder half of the NSCLC puzzle just got a credible new answer. PD-L1-negative non-squamous NSCLC, defined by a tumor proportion score below 1%, represents a population where checkpoint inhibitor monotherapy offers little because there is almost nothing for the immune system to latch onto. These patients have been treated with pembrolizumab plus pemetrexed and platinum chemotherapy as standard first-line care, an approach that has meaningfully extended survival but leaves long-term benefit limited. Kelun-Biotech’s Phase III OptiTROP-Lung06 trial now reports that swapping conventional chemotherapy for the TROP2-directed ADC sacituzumab tirumotecan (sac-TMT) added to pembrolizumab produced a statistically significant and clinically meaningful improvement in progression-free survival at a prespecified interim analysis, with a positive OS trend accompanying it.
The mechanistic rationale here is not speculative. TROP2 expression in non-squamous NSCLC is observed in 82% to 90% of tumor samples and does not track with PD-L1 status, meaning the target is abundant precisely in the population where PD-1 blockade alone struggles most. The hypothesis Kelun-Biotech is validating is that sac-TMT’s payload-induced tumor cell killing generates immunogenic cell death signals that prime the tumor microenvironment, giving pembrolizumab a functional foothold it would otherwise lack. OptiTROP-Lung06 is structured as a direct head-to-head comparison against the current Chinese-approved first-line standard, pembrolizumab plus pemetrexed and platinum, which makes the PFS win far more consequential than a placebo-controlled readout would be. No new safety signals emerged, and the profile was consistent with earlier sac-TMT data.
The strategic weight of this result compounds when placed next to OptiTROP-Lung05, which hit its primary endpoint in PD-L1-positive NSCLC and was published in The Lancet in May 2026. Together, the two trials now provide Phase III evidence spanning essentially the entire driver gene-negative non-squamous NSCLC population by PD-L1 expression status. That is a rare position for any ADC program to occupy. The competitive TROP2 landscape in NSCLC is active: datopotamab deruxtecan received FDA accelerated approval in June 2025 for EGFR-mutated NSCLC in later lines, a distinct population and setting, which means sac-TMT’s first-line, driver gene-negative positioning carves a separate clinical niche. Kelun-Biotech plans to engage China’s Center for Drug Evaluation on the Lung06 data, following an already-submitted new indication application built on Lung05.
The single marker worth tracking now is OS maturity in OptiTROP-Lung06. A positive trend at an interim PFS analysis is encouraging, but conversion to a statistically significant OS benefit at final analysis is what determines whether regulators outside China, particularly FDA and EMA, treat this as registration-grade evidence in its own right or require additional data. That OS readout will define the global ceiling of this program.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
